Clinical Trial Update: Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating homoharringtonine in combination with interferon alfa for chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Homoharringtonine (homoharringtonine)
• Interferon Alfa (interferon alfa)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia | Phase 2 | Status: COMPLETED